Oral Drug Provided Rapid Hereditary Angioedema Relief
A new phase 3 trial shows that deucrictibant significantly reduces symptom time compared to placebo treatments.
Updated on Oct. 10, 2026 in Allergies
Live Poll
Do you believe new oral treatments will improve quality of life for people with chronic conditions?
The oral medication deucrictibant achieved faster symptom relief for hereditary angioedema attacks than placebo in a recent phase 3 trial. Patients receiving the 20-mg treatment experienced shorter times to both initial symptom relief and complete resolution of symptoms.
Why it matters
Most currently available treatments for hereditary angioedema require administration via injection. This oral alternative provides a non-parenteral option for patients managing sudden, painful swelling attacks.
In a phase 3 trial of 134 participants, the 20-mg deucrictibant dose resulted in a median time to symptom relief of 1.28 hours. The study, conducted across 59 sites in 24 countries, found that 83 percent of treated attacks showed relief within 4 hours.
The players
Pharvaris
This biopharmaceutical company is responsible for the development of the oral bradykinin B2 receptor antagonist deucrictibant.
FDA
The Food and Drug Administration is the U.S. federal agency currently reviewing the New Drug Application for the medication.
The details
Deucrictibant functions by directly blocking the bradykinin B2 receptor. In the crossover trial, participants treated qualifying attacks with a single capsule or placebo, with 44 percent of the placebo group requiring rescue medication within 24 hours compared to only 9 percent of those taking the medication.
Timeline
October 8, 2026: Results from the RAPIDe-3 trial were published in The Lancet.
April 23, 2027: The FDA is expected to reach a decision on the deucrictibant New Drug Application.
The Big Picture
This development represents a shift toward non-invasive treatment modalities for patients with hereditary angioedema. The success of the RAPIDe-3 clinical trial suggests a move away from the historical reliance on parenteral rescue medications in favor of convenient, oral alternatives.
Patients who suffer from hereditary angioedema may soon have access to an oral treatment that provides symptom relief in just over an hour. This shift could eliminate the need for traditional injections, significantly improving the daily management of unexpected attacks.
The takeaway
The successful trial of an oral B2 receptor antagonist highlights the potential for shifting treatment paradigms away from injectables. Patients living with hereditary angioedema should consult with their specialists about how emerging oral options might fit into their future care plans.
What happens next
The FDA is scheduled to make a final decision regarding the approval of the deucrictibant New Drug Application on April 23, 2027.
Further reading
Learn more about the latest research in the field of Allergies.
More information
Access the full RAPIDe-3 clinical trial study results01296-1/fulltext) for complete methodology and data.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you believe new oral treatments will improve quality of life for people with chronic conditions?
